[Financial Statements](index=2&type=section&id=Financial%20Statements) This section presents the company's condensed balance sheets, statements of comprehensive loss, changes in shareholders' equity, and cash flows [Condensed Balance Sheets](index=2&type=section&id=Condensed%20Balance%20Sheets) The company's balance sheet as of June 30, 2023, shows a decrease in total assets and shareholders' equity compared to December 31, 2022, primarily driven by a reduction in current assets, particularly short-term deposits Condensed Balance Sheets (in thousands) | Metric | As of June 30, 2023 (in thousands) | As of December 31, 2022 (in thousands) | Change (2023 vs 2022) | | :-------------------------------- | :---------------------------------- | :----------------------------------- | :-------------------- | | Total assets | $8,316 | $12,328 | -$4,012 | | Total current assets | $8,278 | $12,284 | -$4,006 | | Cash and cash equivalents | $5,138 | $4,096 | +$1,042 | | Short term deposit | $1,014 | $6,085 | -$5,071 | | Total liabilities | $1,343 | $1,307 | +$36 | | Total shareholders' equity | $6,973 | $11,021 | -$4,048 | [Condensed Statements of Comprehensive Loss](index=3&type=section&id=Condensed%20Statements%20of%20Comprehensive%20Loss) For the six months ended June 30, 2023, the company experienced an increased net loss and comprehensive loss compared to the same period in 2022, primarily due to higher research and development expenses, partially offset by financial income Condensed Statements of Comprehensive Loss (in thousands) | Metric | For the Six Months Ended June 30, 2023 (in thousands) | For the Six Months Ended June 30, 2022 (in thousands) | Change (2023 vs 2022) | | :------------------------------------ | :-------------------------------------------------- | :-------------------------------------------------- | :-------------------- | | Research and development expenses | $(2,700) | $(1,423) | -$(1,277) | | General and administrative expenses | $(1,968) | $(2,094) | +$126 | | Operating loss | $(4,668) | $(3,517) | -$(1,151) | | Financial income, net | $179 | $- | +$179 | | Net loss and comprehensive loss | $(4,489) | $(3,517) | -$(972) | | Basic and diluted net loss per share | $(4.12) | $(3.25) | -$(0.87) | [Condensed Statements of Changes in Shareholders' Equity](index=4&type=section&id=Condensed%20Statements%20of%20Changes%20in%20Shareholders%27%20Equity) Shareholders' equity decreased significantly from $11,021 thousand at January 1, 2023, to $6,973 thousand by June 30, 2023, primarily due to the net loss incurred during the period, partially offset by share-based compensation Condensed Statements of Changes in Shareholders' Equity (in thousands) | Metric | Balance as of January 1, 2023 (in thousands) | Balance as of June 30, 2023 (in thousands) | Change | | :------------------------------------ | :----------------------------------------- | :---------------------------------------- | :------- | | Total shareholders' equity | $11,021 | $6,973 | -$4,048 | | Accumulated deficit | $(32,519) | $(37,008) | -$(4,489) | | Additional paid-in capital | $43,446 | $43,887 | +$441 | | Share-based compensation to employees and directors (6 months ended June 30, 2023) | N/A | $441 | N/A | | Net loss and comprehensive loss (6 months ended June 30, 2023) | N/A | $(4,489) | N/A | - The number of issued and outstanding ordinary shares increased from **1,081,755** as of December 31, 2022, to **1,090,452** as of June 30, 2023, reflecting share issuance to service providers and adjustments from a reverse share split[3](index=3&type=chunk)[7](index=7&type=chunk) [Condensed Statements of Cash Flows](index=5&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) For the six months ended June 30, 2023, the company significantly reduced its net cash used in operating activities compared to the prior year, while investing activities provided a substantial cash inflow, leading to an overall increase in cash and cash equivalents Condensed Statements of Cash Flows (in thousands) | Metric | For the Six Months Ended June 30, 2023 (in thousands) | For the Six Months Ended June 30, 2022 (in thousands) | Change (2023 vs 2022) | | :------------------------------------------ | :-------------------------------------------------- | :-------------------------------------------------- | :-------------------- | | Net cash used in operating activities | $(3,955) | $(2,699) | -$(1,256) | | Net cash provided by investing activities | $5,000 | $(3) | +$5,003 | | Change in cash, cash equivalents and restricted cash | $1,042 | $(2,702) | +$3,744 | | Cash, cash equivalents and restricted cash at end of period | $5,148 | $13,869 | -$8,721 | - The positive cash flow from investing activities in 2023 was primarily driven by proceeds from short-term deposits (**$6,000 thousand**), offsetting purchases of short-term deposits (**$1,000 thousand**)[9](index=9&type=chunk) [Notes to Condensed Unaudited Financial Statements](index=6&type=section&id=Notes%20to%20Condensed%20Unaudited%20Financial%20Statements) This section provides detailed notes explaining the company's financial statements, including significant accounting policies, going concern issues, and subsequent events [NOTE 1: GENERAL](index=6&type=section&id=NOTE%201%3A%20GENERAL) PainReform Ltd. is a clinical-stage specialty pharmaceutical company focused on post-surgical pain relief. The company has incurred significant losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern, necessitating further capital raising. Additionally, the second part of its Phase 3 clinical trial faces delays due to an FDA deficiency notice to its API supplier - The Company is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, aiming to provide extended post-surgical pain relief without repeated dose administration and reduce opiate use[15](index=15&type=chunk) - The Company has incurred significant losses and negative cash flows from operations, with net losses of **$4,489 thousand** and **$3,517 thousand** for the six-month periods ended June 30, 2023 and 2022, respectively[11](index=11&type=chunk) - As of June 30, 2023, the accumulated deficit was **$37,008 thousand**, and the Company does not have sufficient resources to fund operations until the end of its Phase III study, raising substantial doubt about its ability to continue as a going concern[11](index=11&type=chunk)[13](index=13&type=chunk) - Management plans to continue capital raising through equity, debt, or strategic partnerships, but there are no assurances of obtaining the necessary financing[14](index=14&type=chunk) - The second part of the Phase 3 trial for PRF-110 is expected to commence once the FDA resolves a deficiency notice issued to the Company's API supplier, which does not relate to the PRF-110 product itself[14](index=14&type=chunk) [NOTE 2: UNAUDITED CONDENSED FINANCIAL STATEMENTS](index=7&type=section&id=NOTE%202%3A%20UNAUDITED%20CONDENSED%20FINANCIAL%20STATEMENTS) These unaudited condensed financial statements are prepared in accordance with U.S. GAAP, consistent with the annual report, but omit certain disclosures. They reflect management's necessary adjustments and are not indicative of future results. The company is exposed to foreign exchange risk due to Israeli operations and has retroactively applied a 1-for-10 reverse share split. Global market volatility from geopolitical tensions is also noted as a potential risk - The unaudited condensed financial statements are prepared in accordance with U.S. GAAP, consistent with the Company's 2022 Annual Report on Form 20-F, but certain information and disclosures normally included in annual financial statements have been omitted[17](index=17&type=chunk)[18](index=18&type=chunk) - Operating results for the six months ended June 30, 2023, are not necessarily indicative of the results that may be expected for the full year or any other future period[20](index=20&type=chunk) - The Company is exposed to exchange rate risks between the New Israeli Shekel (NIS) and the U.S. dollar, which could materially affect financial results, although Israeli inflation did not have a material adverse effect during the periods presented[21](index=21&type=chunk) - In June 2023, the Company effected a **1-for-10 reverse share split**, and all related share and per share data have been retroactively applied to the financial statements for all periods presented[21](index=21&type=chunk) - U.S. and global markets are experiencing volatility and disruption due to geopolitical tensions and the military conflict between Russia and Ukraine, which could affect the Company's business, financial condition, and operating results[21](index=21&type=chunk) [NOTE 3: SIGNIFICANT ACCOUNTING POLICIES](index=8&type=section&id=NOTE%203%3A%20SIGNIFICANT%20ACCOUNTING%20POLICIES) The significant accounting policies applied in these unaudited condensed financial statements are consistent with those used in the Company's most recent annual financial statements - The significant accounting policies applied in the preparation of these unaudited condensed financial statements are consistent with those used in the Company's most recent annual financial statements in connection with its Annual Report on Form 20-F[22](index=22&type=chunk) [NOTE 4: SHAREHOLDERS' EQUITY](index=8&type=section&id=NOTE%204%3A%20SHAREHOLDERS%27%20EQUITY) This note details the company's outstanding warrants and share-based compensation plans, including options granted to employees and directors. It also confirms the retroactive application of a 1-for-10 reverse share split to all share-related data [Warrants and warrants units](index=8&type=section&id=Warrants%20and%20warrants%20units) As of June 30, 2023, the company had 3,950,217 warrants outstanding with various issuance dates, exercise prices, and expiration dates, including IPO, PIPE, and underwriter warrants Warrants Outstanding as of June 30, 2023 | Type | Issuance Date | Number of warrants | Exercise price (**) | Exercisable through | | :-------------------------------- | :---------------- | :----------------- | :------------------ | :------------------ | | August 2019 warrants | August 22, 2019 | 205,268 | $67.2 (*) | August 22, 2024 | | December 2019 warrants | December 9, 2019 | 92,321 | $67.2 (*) | December 8, 2024 | | Warrants 2019 Convertible Notes to placement agent | December 9, 2019 | 55,785 | $67.2 (*) | December 8, 2024 | | Warrants to underwriters | September 3, 2020 | 125,000 | $100.0 | September 1, 2025 | | Warrants to underwriters | October 5, 2020 | 375,000 | $88.0 | September 3, 2025 | | IPO warrants | September 3, 2020 | 2,812,170 | $88.0 | September 3, 2025 | | PIPE warrants | March 11, 2021 | 232,500 | $46.0 | September 10, 2026 | | Warrants to PIPE placement agent | March 11, 2021 | 52,173 | $50.6 | March 8, 2026 | | **TOTAL** | | **3,950,217** | | | - All exercise prices have been retroactively adjusted to reflect a **1-for-10 reverse share split**[24](index=24&type=chunk) [Share-based compensation](index=9&type=section&id=Share-based%20compensation) The company maintains two share option plans (2008 and 2019 Plans) for employees and directors. In June 2023, 54,000 options were granted to board members under the 2019 Plan at an exercise price of $5.89 per share, with a grant-date fair value of $3.20 per option 2008 Share Option Plan (Options Outstanding and Exercisable) | Metric | As of June 30, 2023 | As of December 31, 2022 | | :-------------------------------- | :------------------ | :-------------------- | | Options outstanding | 15,388 | 15,388 | | Weighted average exercise price | $2.40 | $2.40 | | Weighted average remaining contractual life | 0.75 years | 1.25 years | | Options exercisable | 15,388 | 15,388 | 2019 Share Option Plan (Options Outstanding and Exercisable) | Metric | As of June 30, 2023 | As of December 31, 2022 | | :-------------------------------- | :------------------ | :-------------------- | | Options outstanding | 187,994 | 133,994 | | Weighted average exercise price | $11.94 | $14.4 | | Weighted average remaining contractual life | 9.20 years | 9.39 years | | Options exercisable | 116,416 | 133,994 | - On June 8, 2023, shareholders approved the grant of **54,000 options** to two current board members and the Chairman, each receiving **18,000 options** at an exercise price of **$5.89 per share**. Fifty percent vested upon grant, with the remainder vesting quarterly over 36 months[27](index=27&type=chunk) - The grant-date fair value for the June 2023 options was **$3.20 per option**, based on an average expected term of **5.36 years**, a risk-free interest rate of **3.85%**, volatility of **90.43%**, and zero dividend yield[27](index=27&type=chunk) - A **1-for-10 reverse share split** was effected in June 2023, consolidating shares and retroactively adjusting all related share and per share data in the financial statements and notes for all periods presented[34](index=34&type=chunk) [NOTE 5: LOSS PER SHARE](index=11&type=section&id=NOTE%205%3A%20LOSS%20PER%20SHARE) Basic loss per share is calculated based on net loss and weighted average ordinary shares. For the periods ended June 30, 2023, and 2022, all outstanding share options, restricted shares, and warrants were anti-dilutive and thus excluded from the diluted loss per share calculation - Basic loss per share is computed by dividing the net loss by the weighted average number of Ordinary Shares and vested Ordinary Shares issuable for little or no further consideration outstanding during the period[30](index=30&type=chunk) - For the six months ended June 30, 2023, and 2022, all outstanding share options, restricted shares, and warrants were excluded from the calculation of diluted net loss per share because they were anti-dilutive[31](index=31&type=chunk) [NOTE 6: COMMITMENTS AND CONTINGENCIES](index=11&type=section&id=NOTE%206%3A%20COMMITMENTS%20AND%20CONTINGENCIES) The company has agreements with Lotus Clinical Research for its Phase 3 trials of PRF-110, with updated milestone and subject payment terms. Clinical trial expenses are recognized as incurred, with prepaid amounts recorded. Additionally, the company issued shares to a consultant in February 2023 - The Company entered into Master Clinical Research Organization Agreements with Lotus Clinical Research for its planned Phase 3 trials of PRF-110, which commenced in March 2023[32](index=32&type=chunk) - The total milestone completion payment was updated to **$5.6 million**, and the payment for the actual number of evaluable subjects was updated to **$8.6 million**[32](index=32&type=chunk) - Clinical trial expenses are charged to research and development expenses as incurred. As of June 30, 2023, **$1,962 thousand** was accounted for as prepaid clinical trial expenses, and **$2,042 thousand** was recognized as clinical trial expenses during the six months ended June 2023[33](index=33&type=chunk)[34](index=34&type=chunk) - In February 2023, the Company issued **8,697 Ordinary Shares** to a consultant in connection with a second grant approved in May 2022[34](index=34&type=chunk) [NOTE 7: FINANCIAL INCOME, NET](index=12&type=section&id=NOTE%207%3A%20FINANCIAL%20INCOME%2C%20NET) For the six months ended June 30, 2023, the company reported net financial income of $179 thousand, primarily driven by interest income, a significant increase compared to the prior year Financial Income, Net (in thousands) | Metric | Six Months ended June 30, 2023 (in thousands) | Six Months ended June 30, 2022 (in thousands) | | :------------------------ | :------------------------------------------ | :------------------------------------------ | | Bank fees | $(8) | $(7) | | Interest income | $190 | $- | | Exchange rate differences | $(3) | $7 | | **Total financial income, net** | **$179** | **$-** | [NOTE 8: FINANCIAL INSTRUMENTS](index=12&type=section&id=NOTE%208%3A%20FINANCIAL%20INSTRUMENTS) The carrying amounts of the company's cash equivalents, restricted cash, trade payables, and accrued expenses are considered to approximate their fair value due to their short-term nature - The carrying amount of cash equivalents, restricted cash, account payables, and accrued expenses approximate their fair value due to their short-term characteristics[36](index=36&type=chunk) [NOTE 9: SUBSEQUENT EVENTS](index=12&type=section&id=NOTE%209%3A%20SUBSEQUENT%20EVENTS) In July 2023, the company completed two registered direct offerings and concurrent private placements of warrants, raising approximately $4.2 million in gross proceeds and $3.6 million in net proceeds. These transactions involved the sale of ordinary shares and pre-funded warrants, which were fully exercised - On July 14, 2023, the Company sold **117,930 Ordinary Shares** and pre-funded warrants for **183,300 Ordinary Shares** in a registered direct offering and private placement, generating gross proceeds of approximately **$2.7 million** and net proceeds of **$2.3 million**[38](index=38&type=chunk) - On July 18, 2023, another registered direct offering and private placement resulted in the sale of **145,000 Ordinary Shares** and pre-funded warrants for **21,666 Ordinary Shares**, yielding gross proceeds of approximately **$1.5 million** and net proceeds of **$1.3 million**[38](index=38&type=chunk) - Both offerings included the issuance of unregistered warrants to purchase additional Ordinary Shares at an exercise price of **$9.00 per share**, and all pre-funded warrants were exercised in full[38](index=38&type=chunk)

Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF MARCH 31, 2023 U.S. DOLLARS IN THOUSANDS UNAUDITED F - 2 PAINREFORM LTD. CONDENSED STATEMENTS OF COMPREHENSIVE LOSS U.S. dollars in thousands (except share and per share data) INDEX | | Page | | --- | --- | | Condensed Balance Sheets | F-2 | | Condensed Statements of Comprehensive Loss | F-3 | | Condensed Statements of Changes in Shareholders' Equity | F-4 | | Condensed Statements of Cash Flows | F-5 | | Notes to Condensed Financial Statement ...

Financial Condition - As of December 31, 2022, the company had total cash and cash equivalents of $10.2 million, indicating a need for substantial additional funding to continue operations[54]. - The company incurred operating losses of approximately $8.8 million, $7.2 million, and $4.0 million for the years ended December 31, 2022, 2021, and 2020, respectively, with an accumulated deficit of $31.5 million as of December 31, 2022[55]. - The company expects to continue incurring losses and negative cash flows from operations until its product, PRF-110, reaches commercial profitability, with sufficient resources only to fund operations through the end of Q4 2023[62]. - The company may need to raise additional capital through public or private offerings, and failure to do so could result in delays or reductions in research and development programs[60]. - The company has not yet commercialized any products or technologies and may never achieve profitability, as it has never generated revenues[57]. Product Development and Clinical Trials - The company is dependent on the success of its initial product candidate, PRF-110, which began clinical trials in March 2023, and any delays or failures in these trials could materially harm the business[48]. - PRF-110 requires substantial investment and successful completion of additional clinical trials before any revenue can be generated[73]. - The company has experienced delays in manufacturing clinical trial batches, which could further harm its business if not resolved[75]. - Clinical trials carry a high risk of failure, and setbacks can occur at any stage, potentially delaying or terminating development efforts[93]. - The Phase 3 clinical trial for PRF-110 was initiated in March 2023, targeting pain treatment for patients undergoing bunionectomy[216]. Regulatory and Compliance Risks - Regulatory approval, once obtained, is subject to continual review, and there is no assurance that approval will not be withdrawn or restricted[94]. - Increased scrutiny of the FDA's approval process may significantly delay or prevent marketing approval for the company's products[114]. - The company must establish drug development and marketing arrangements with third parties to successfully commercialize its drug candidates[96]. - Compliance with patent application processes is essential; non-compliance could result in loss of patent rights, allowing competitors to enter the market[135]. - The company is committed to compliance with anti-corruption laws, but risks remain regarding potential violations that could lead to significant penalties[162]. Supply Chain and Manufacturing - The company is reliant on a single supplier for critical materials and components used in manufacturing, which poses a risk to its operations[48]. - The company relies on third-party manufacturers for clinical trial supplies and faces risks if these manufacturers fail to meet regulatory standards or deliver on time[78]. - The company is dependent on a single supplier for critical materials used in PRF-110 manufacturing, posing a risk of supply chain interruptions[79]. - The manufacturing process for PRF-110 has been enhanced to improve efficiency and scalability, contributing to a competitive cost of goods[227]. - Manufacturing operations for PRF-110 have been shifted to Pharmaceutics International in the U.S. after previous delays with a former CMO in Israel due to regulatory and operational issues[231][237]. Market and Competitive Landscape - Market acceptance of PRF-110 is critical, as it is expected to generate substantially all revenues for the foreseeable future; failure to achieve acceptance would harm business prospects[99]. - The pharmaceutical industry is highly competitive, and the company may face challenges if competitors develop more effective or less expensive products[100]. - The North American post-operative pain treatment market was estimated at $12 billion and is expected to reach $16 billion and $45 billion worldwide by the end of 2026[218]. - The company aims to address unmet medical needs in the post-operative pain market, which has a largely untapped opportunity[223]. Intellectual Property and Legal Risks - The company is dependent on proprietary technology and faces risks related to intellectual property rights and potential infringement claims[127]. - Maintaining patent protection is critical; failure to do so could allow competitors to commercialize similar products, adversely affecting the company's market position[129]. - The company faces significant risks related to intellectual property, including potential litigation that could distract personnel and incur substantial expenses[142]. - Employees may claim compensation for inventions made during their employment, which could impact future revenue and profitability[157]. Operational Challenges - The company faces challenges in attracting and retaining skilled personnel, which is critical for its drug development efforts[86]. - The ongoing military conflict between Russia and Ukraine has created economic uncertainty that may adversely affect the company's operations[53]. - The company faces risks from IT system failures and cybersecurity attacks, which could disrupt operations and lead to significant financial and reputational harm[117]. - The company incurs significant legal, accounting, and compliance costs as a public entity, which were not present when it operated as a private company[182]. Shareholder and Market Considerations - The company received a notice from Nasdaq on August 16, 2022, indicating that the bid price of its ordinary shares had closed below the minimum requirement of $1.00 for over 30 consecutive trading days[172]. - As of February 7, 2023, the company was granted a second 180-day compliance period to regain Nasdaq listing compliance, with a requirement to close at or above $1.00 per share for at least 10 consecutive trading days[173]. - Future issuance of ordinary shares could dilute existing shareholders' interests, potentially adversely affecting the market price of the shares[194]. - The market price of ordinary shares may be highly volatile, influenced by various factors including regulatory changes and competitive actions[199]. Strategic Partnerships and Alliances - Strategic alliances are essential for business expansion, but the company may face challenges in identifying suitable partners and managing integration[123]. - The company plans to launch PRF-110 either independently or with a strategic partner experienced in surgical product marketing[220]. - Future product development will focus on expanding the pipeline using the extended-release drug-delivery system for various surgical indications, including breast augmentation and orthopedic procedures[234][235].

CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2022 UNAUDITED U.S. DOLLARS IN THOUSANDS INDEX | | Page | | --- | --- | | Condensed Balance Sheets | F-2 | | Condensed Statements of Comprehensive Loss | F-3 | | Condensed Statements of Changes in Shareholders' Equity | F-4 | | Condensed Statements of Cash Flows | F-5 | | Notes to Condensed Financial Statements | F-6 - F-11 | Exhibit 99.1 PAINREFORM LTD. PAINREFORM LTD. CONDENSED BALANCE SHEETS (UNAUDITED) U.S. dollars in thousands (except share and per share da ...

Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS INDEX | | Page | | --- | --- | | Condensed Balance Sheets | F-2 | | Condensed Statements of Comprehensive Loss | F-3 | | Condensed Statements of Changes in Shareholders' Equity | F-4 | | Condensed Statements of Cash Flows | F-5 | | Notes to Condensed Financial Statements | F-6 - F-11 | PAINREFORM LTD. CONDENSED BALANCE SHEETS U.S. dollars in thousands | | | | | As of | | --- | --- | --- | --- | --- | | | As of | | | December | | | March 31, | | | 3 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 ...

Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF September 30, 2021 UNAUDITED U.S. DOLLARS IN THOUSANDS INDEX | | Page | | --- | --- | | Condensed Balance Sheets | F-2 | | Condensed Statements of Comprehensive Loss | F-3 | | Condensed Statement of Changes in Convertible Preferred Shares and Shareholders' Equity (deficit) | F-4 - F-5 | | Condensed Statements of Cash Flows | F-6 | | Notes to Condensed Financial Statements | F-7 - F-12 | PAINREFORM LTD. CONDENSED BALANCE SHEETS (UNAUDITED) U.S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Commission File No.: 001-39481 PAINREFORM LTD. (Exact name of registrant as specified in its charter) Translation of registrant's name into English: Not applicable Israel (Jurisdiction of incorporation or organization) (Address of principal executive of ices) Ilan Hadar Chief Executive Officer 4 Bruria ...